Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
OpenAI reverses course, retains nonprofit board control and converts to a Public Benefit Corporation to balance profit-making and its charitable mission.
Palantir raises annual revenue forecast amid strong AI demand, positioning it as a leader in data analytics and software industry.
Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
OpenAI reverses course, retains nonprofit board control and converts to a Public Benefit Corporation to balance profit-making and its charitable mission.
Palantir raises annual revenue forecast amid strong AI demand, positioning it as a leader in data analytics and software industry.